Oral / Intravenous · GLP-1 / GIP / glucagon triple
LY4086940
2 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
2
Ongoing
1
Recruiting
0
Completed
1
Sites
50
Countries
3
Endpoints
8
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Not yet recruiting
1
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
5
Weight & body composition
3
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07890376A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes | LY4086940 Obesity / overweight | - | Ph 2 | Not yet recruiting | 46 | Jan 2028 | - | |
| NCT06945419A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | LY4086940 Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI 22-35 | Ph 1 | Completed | 5 | Aug 2026 | - |
Showing 1-2 of 2 trials